| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burkitt Lymphoma | 37 | 2026 | 74 | 9.120 |
Why?
|
| Malaria, Falciparum | 46 | 2026 | 234 | 8.310 |
Why?
|
| Epstein-Barr Virus Infections | 26 | 2025 | 105 | 6.940 |
Why?
|
| Herpesvirus 4, Human | 33 | 2025 | 199 | 6.860 |
Why?
|
| Plasmodium falciparum | 40 | 2026 | 257 | 6.240 |
Why?
|
| Kenya | 55 | 2026 | 97 | 3.150 |
Why?
|
| Merozoite Surface Protein 1 | 10 | 2016 | 24 | 2.120 |
Why?
|
| Malaria Vaccines | 9 | 2026 | 41 | 1.980 |
Why?
|
| Antigens, Protozoan | 13 | 2025 | 63 | 1.890 |
Why?
|
| Child, Preschool | 44 | 2026 | 2061 | 1.770 |
Why?
|
| Child | 51 | 2026 | 4607 | 1.700 |
Why?
|
| Malaria | 13 | 2023 | 158 | 1.590 |
Why?
|
| Sarcoma, Kaposi | 2 | 2023 | 17 | 1.410 |
Why?
|
| Interferon-gamma | 11 | 2017 | 574 | 1.330 |
Why?
|
| Antibodies, Protozoan | 12 | 2025 | 56 | 1.300 |
Why?
|
| Endemic Diseases | 13 | 2021 | 23 | 1.250 |
Why?
|
| Killer Cells, Natural | 3 | 2021 | 220 | 1.230 |
Why?
|
| Infant | 30 | 2026 | 1693 | 1.190 |
Why?
|
| Coinfection | 5 | 2020 | 59 | 1.110 |
Why?
|
| Interleukin-10 | 5 | 2016 | 164 | 1.100 |
Why?
|
| Adolescent | 35 | 2026 | 6297 | 1.070 |
Why?
|
| Genome, Viral | 4 | 2025 | 144 | 1.050 |
Why?
|
| B-Lymphocytes | 4 | 2025 | 563 | 1.010 |
Why?
|
| Humans | 106 | 2026 | 65140 | 1.000 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 17 | 0.950 |
Why?
|
| Palatine Tonsil | 1 | 2025 | 9 | 0.920 |
Why?
|
| Lymphoma, B-Cell | 1 | 2025 | 63 | 0.880 |
Why?
|
| Immunoglobulin G | 15 | 2026 | 465 | 0.870 |
Why?
|
| Neoplasms | 3 | 2026 | 1368 | 0.840 |
Why?
|
| Immune System | 2 | 2019 | 132 | 0.820 |
Why?
|
| Antibodies, Viral | 8 | 2026 | 325 | 0.820 |
Why?
|
| Protozoan Proteins | 10 | 2017 | 132 | 0.720 |
Why?
|
| CD56 Antigen | 2 | 2020 | 16 | 0.710 |
Why?
|
| Seroepidemiologic Studies | 7 | 2023 | 51 | 0.700 |
Why?
|
| Papillomavirus Infections | 4 | 2025 | 134 | 0.640 |
Why?
|
| Herpesviridae Infections | 1 | 2020 | 25 | 0.640 |
Why?
|
| Herpesviridae | 1 | 2020 | 15 | 0.640 |
Why?
|
| Viral Load | 9 | 2021 | 230 | 0.630 |
Why?
|
| Receptors, IgG | 1 | 2020 | 41 | 0.620 |
Why?
|
| Female | 44 | 2026 | 34018 | 0.600 |
Why?
|
| Sickle Cell Trait | 2 | 2013 | 8 | 0.600 |
Why?
|
| Genotype | 10 | 2024 | 673 | 0.590 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 3 | 2020 | 19 | 0.590 |
Why?
|
| Whole Genome Sequencing | 3 | 2025 | 85 | 0.580 |
Why?
|
| Immunity, Humoral | 2 | 2016 | 39 | 0.580 |
Why?
|
| Tumor Virus Infections | 2 | 2016 | 26 | 0.570 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 10 | 2023 | 450 | 0.560 |
Why?
|
| Male | 33 | 2026 | 31047 | 0.540 |
Why?
|
| Vaccination | 4 | 2026 | 377 | 0.540 |
Why?
|
| Parasitemia | 8 | 2016 | 49 | 0.530 |
Why?
|
| T-Lymphocytes | 5 | 2017 | 1008 | 0.510 |
Why?
|
| Oncogenic Viruses | 1 | 2016 | 2 | 0.500 |
Why?
|
| Immunologic Surveillance | 1 | 2016 | 22 | 0.500 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2025 | 509 | 0.460 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2012 | 241 | 0.450 |
Why?
|
| Adult | 29 | 2026 | 17358 | 0.450 |
Why?
|
| Polymerase Chain Reaction | 9 | 2015 | 513 | 0.450 |
Why?
|
| Animals | 32 | 2025 | 21345 | 0.440 |
Why?
|
| Viral Matrix Proteins | 2 | 2025 | 50 | 0.440 |
Why?
|
| Immunity, Cellular | 2 | 2013 | 170 | 0.430 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 221 | 0.430 |
Why?
|
| Antimalarials | 5 | 2019 | 126 | 0.420 |
Why?
|
| Survival Rate | 1 | 2016 | 844 | 0.410 |
Why?
|
| Interleukin-6 | 1 | 2014 | 324 | 0.380 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 2701 | 0.380 |
Why?
|
| HIV Infections | 5 | 2022 | 955 | 0.370 |
Why?
|
| Young Adult | 13 | 2025 | 4809 | 0.370 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2025 | 151 | 0.360 |
Why?
|
| Cytokines | 3 | 2025 | 952 | 0.360 |
Why?
|
| Age Factors | 9 | 2020 | 1586 | 0.350 |
Why?
|
| Biomarkers | 2 | 2016 | 1480 | 0.350 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2022 | 29 | 0.350 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 687 | 0.340 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2016 | 676 | 0.340 |
Why?
|
| Alleles | 7 | 2023 | 453 | 0.330 |
Why?
|
| History, 21st Century | 4 | 2021 | 179 | 0.320 |
Why?
|
| Microbiota | 2 | 2023 | 169 | 0.310 |
Why?
|
| Immunologic Memory | 4 | 2025 | 284 | 0.290 |
Why?
|
| Tumor Escape | 1 | 2008 | 16 | 0.280 |
Why?
|
| Nanopores | 2 | 2025 | 14 | 0.280 |
Why?
|
| Germinal Center | 2 | 2025 | 39 | 0.280 |
Why?
|
| Cancer Vaccines | 1 | 2008 | 51 | 0.280 |
Why?
|
| Genetic Variation | 4 | 2025 | 394 | 0.280 |
Why?
|
| Family Characteristics | 1 | 2008 | 46 | 0.270 |
Why?
|
| Human papillomavirus 16 | 2 | 2025 | 20 | 0.270 |
Why?
|
| Sensitivity and Specificity | 4 | 2025 | 1163 | 0.260 |
Why?
|
| Haplotypes | 5 | 2014 | 134 | 0.260 |
Why?
|
| Prevalence | 7 | 2014 | 1445 | 0.260 |
Why?
|
| Child, Hospitalized | 1 | 2026 | 20 | 0.240 |
Why?
|
| Cross Reactions | 1 | 2026 | 139 | 0.240 |
Why?
|
| Body Temperature Regulation | 1 | 2025 | 21 | 0.240 |
Why?
|
| Virus Activation | 3 | 2011 | 23 | 0.230 |
Why?
|
| Serpins | 1 | 2025 | 18 | 0.230 |
Why?
|
| Case-Control Studies | 4 | 2014 | 1141 | 0.230 |
Why?
|
| Odds Ratio | 3 | 2020 | 754 | 0.230 |
Why?
|
| Flow Cytometry | 4 | 2026 | 663 | 0.230 |
Why?
|
| Lipolysis | 1 | 2025 | 47 | 0.230 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2025 | 44 | 0.220 |
Why?
|
| Hepatitis B Antibodies | 1 | 2024 | 9 | 0.220 |
Why?
|
| Middle Aged | 17 | 2024 | 18273 | 0.220 |
Why?
|
| Hepatitis B Vaccines | 1 | 2024 | 16 | 0.220 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2024 | 20 | 0.220 |
Why?
|
| Hepatitis B | 1 | 2024 | 28 | 0.210 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2025 | 82 | 0.210 |
Why?
|
| History, 20th Century | 3 | 2021 | 232 | 0.210 |
Why?
|
| Saliva | 1 | 2024 | 100 | 0.210 |
Why?
|
| Public Health | 1 | 2026 | 186 | 0.200 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2003 | 3 | 0.200 |
Why?
|
| Disease Models, Animal | 3 | 2023 | 2293 | 0.200 |
Why?
|
| Pregnancy Complications, Parasitic | 2 | 2001 | 7 | 0.200 |
Why?
|
| Infant, Newborn | 9 | 2024 | 1422 | 0.200 |
Why?
|
| Adipocytes | 1 | 2025 | 273 | 0.200 |
Why?
|
| Aflatoxins | 1 | 2022 | 2 | 0.190 |
Why?
|
| Neutrophils | 1 | 2026 | 395 | 0.190 |
Why?
|
| Nucleocapsid Proteins | 1 | 2023 | 34 | 0.190 |
Why?
|
| Placenta | 2 | 2001 | 69 | 0.190 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 19 | 0.190 |
Why?
|
| Rituximab | 1 | 2023 | 89 | 0.190 |
Why?
|
| Erythrocytes | 4 | 2014 | 146 | 0.190 |
Why?
|
| Gene Frequency | 3 | 2014 | 122 | 0.180 |
Why?
|
| Aged | 12 | 2024 | 14965 | 0.180 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 1565 | 0.180 |
Why?
|
| MicroRNAs | 2 | 2019 | 713 | 0.180 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 114 | 0.180 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 263 | 0.180 |
Why?
|
| RNA, Viral | 2 | 2019 | 266 | 0.170 |
Why?
|
| Receptors, KIR | 1 | 2021 | 4 | 0.170 |
Why?
|
| DNA, Viral | 2 | 2020 | 231 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 415 | 0.170 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2022 | 184 | 0.170 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2020 | 11 | 0.160 |
Why?
|
| Dysbiosis | 1 | 2021 | 74 | 0.160 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2020 | 6 | 0.160 |
Why?
|
| Cells, Cultured | 3 | 2016 | 2188 | 0.160 |
Why?
|
| Parasites | 1 | 2020 | 15 | 0.160 |
Why?
|
| Africa South of the Sahara | 3 | 2015 | 18 | 0.160 |
Why?
|
| Mentors | 1 | 2021 | 118 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2022 | 641 | 0.150 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 1282 | 0.150 |
Why?
|
| Fetal Growth Retardation | 1 | 1999 | 21 | 0.150 |
Why?
|
| Phenotype | 1 | 2023 | 1233 | 0.150 |
Why?
|
| Global Health | 1 | 2021 | 181 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2011 | 247 | 0.150 |
Why?
|
| Hemoglobin, Sickle | 2 | 2013 | 7 | 0.150 |
Why?
|
| Mice | 6 | 2025 | 11119 | 0.150 |
Why?
|
| Virus Replication | 2 | 2023 | 323 | 0.150 |
Why?
|
| Retrospective Studies | 4 | 2026 | 6872 | 0.150 |
Why?
|
| Iron Chelating Agents | 1 | 1999 | 7 | 0.150 |
Why?
|
| Deferoxamine | 1 | 1999 | 5 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 414 | 0.140 |
Why?
|
| Time Factors | 4 | 2016 | 3762 | 0.140 |
Why?
|
| Viral Proteins | 1 | 2020 | 270 | 0.140 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 361 | 0.140 |
Why?
|
| Massachusetts | 1 | 2024 | 2145 | 0.140 |
Why?
|
| HIV-1 | 2 | 2020 | 706 | 0.140 |
Why?
|
| Risk Factors | 6 | 2019 | 5429 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 730 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2021 | 262 | 0.130 |
Why?
|
| Adenoviruses, Simian | 1 | 2017 | 2 | 0.130 |
Why?
|
| Incidence | 4 | 2016 | 1419 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2020 | 274 | 0.130 |
Why?
|
| Mutation | 2 | 2017 | 2661 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 191 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2020 | 742 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 92 | 0.120 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 794 | 0.120 |
Why?
|
| Cell Differentiation | 2 | 2021 | 1386 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 64 | 0.120 |
Why?
|
| Antibody Formation | 1 | 2016 | 110 | 0.120 |
Why?
|
| Life Cycle Stages | 2 | 2013 | 20 | 0.120 |
Why?
|
| RNA, Messenger | 3 | 2017 | 1574 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2026 | 3308 | 0.120 |
Why?
|
| Pregnancy | 6 | 2024 | 2372 | 0.120 |
Why?
|
| Antigens, Viral | 3 | 2016 | 130 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2016 | 135 | 0.110 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 26 | 0.110 |
Why?
|
| Recurrence | 3 | 2012 | 657 | 0.110 |
Why?
|
| Monitoring, Immunologic | 1 | 2015 | 3 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2016 | 210 | 0.110 |
Why?
|
| Inflammation | 1 | 2021 | 1192 | 0.110 |
Why?
|
| Biopsy | 1 | 2016 | 456 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 583 | 0.110 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 544 | 0.110 |
Why?
|
| Artemisinins | 1 | 2014 | 42 | 0.100 |
Why?
|
| Gene Expression Regulation | 3 | 2010 | 1630 | 0.100 |
Why?
|
| Blood | 1 | 2013 | 31 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2025 | 312 | 0.100 |
Why?
|
| Acute Disease | 1 | 2015 | 663 | 0.100 |
Why?
|
| DNA, Protozoan | 3 | 2012 | 51 | 0.100 |
Why?
|
| Risk | 1 | 2014 | 374 | 0.100 |
Why?
|
| Models, Biological | 2 | 2017 | 1192 | 0.100 |
Why?
|
| DNA Primers | 1 | 2013 | 301 | 0.100 |
Why?
|
| Age Distribution | 4 | 2007 | 262 | 0.100 |
Why?
|
| Phylogeny | 2 | 2025 | 388 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2016 | 2620 | 0.090 |
Why?
|
| Models, Immunological | 1 | 2012 | 85 | 0.090 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2012 | 12 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 464 | 0.090 |
Why?
|
| Immunodominant Epitopes | 2 | 2009 | 59 | 0.090 |
Why?
|
| Liver | 2 | 2013 | 871 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 309 | 0.090 |
Why?
|
| Arbovirus Infections | 1 | 2011 | 3 | 0.090 |
Why?
|
| Hospital Mortality | 1 | 2016 | 875 | 0.090 |
Why?
|
| Polymorphism, Genetic | 3 | 2014 | 198 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 740 | 0.080 |
Why?
|
| Base Sequence | 1 | 2013 | 1332 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2017 | 918 | 0.080 |
Why?
|
| Peptide Library | 1 | 2010 | 33 | 0.080 |
Why?
|
| Malnutrition | 1 | 2010 | 40 | 0.080 |
Why?
|
| Computational Biology | 3 | 2019 | 367 | 0.070 |
Why?
|
| Immunoglobulin D | 2 | 2025 | 9 | 0.070 |
Why?
|
| Uganda | 1 | 2009 | 38 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 2008 | 417 | 0.070 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2009 | 64 | 0.070 |
Why?
|
| Virus Latency | 1 | 2008 | 31 | 0.070 |
Why?
|
| Sporozoites | 1 | 2008 | 7 | 0.070 |
Why?
|
| Protein Subunits | 2 | 2009 | 169 | 0.070 |
Why?
|
| Epitope Mapping | 1 | 2008 | 52 | 0.070 |
Why?
|
| Fetal Blood | 1 | 2008 | 73 | 0.070 |
Why?
|
| Prognosis | 2 | 2025 | 1784 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2025 | 261 | 0.070 |
Why?
|
| Immunity, Innate | 2 | 2015 | 827 | 0.070 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2007 | 10 | 0.070 |
Why?
|
| Microspheres | 1 | 2007 | 55 | 0.070 |
Why?
|
| Housing | 1 | 2008 | 74 | 0.070 |
Why?
|
| Smallpox Vaccine | 1 | 2007 | 11 | 0.060 |
Why?
|
| HLA-A2 Antigen | 1 | 2007 | 62 | 0.060 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 434 | 0.060 |
Why?
|
| Microscopy | 3 | 2015 | 99 | 0.060 |
Why?
|
| Receptors, LDL | 1 | 2025 | 35 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 662 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 202 | 0.060 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2005 | 8 | 0.060 |
Why?
|
| Vincristine | 1 | 2005 | 26 | 0.060 |
Why?
|
| Adipokines | 1 | 2025 | 36 | 0.060 |
Why?
|
| Receptors, CXCR5 | 1 | 2025 | 3 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2025 | 25 | 0.060 |
Why?
|
| Macrolides | 1 | 2005 | 38 | 0.060 |
Why?
|
| Hepatitis B virus | 1 | 2024 | 10 | 0.050 |
Why?
|
| Democratic Republic of the Congo | 1 | 2024 | 19 | 0.050 |
Why?
|
| Immunoassay | 1 | 2025 | 71 | 0.050 |
Why?
|
| Immunization Schedule | 1 | 2024 | 22 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2025 | 125 | 0.050 |
Why?
|
| Thermogenesis | 1 | 2025 | 127 | 0.050 |
Why?
|
| Tanzania | 1 | 2024 | 40 | 0.050 |
Why?
|
| Adipose Tissue, Brown | 1 | 2025 | 124 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2004 | 26 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2004 | 80 | 0.050 |
Why?
|
| Genetics, Population | 1 | 2004 | 45 | 0.050 |
Why?
|
| Receptors, KIR3DS1 | 1 | 2023 | 3 | 0.050 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2023 | 6 | 0.050 |
Why?
|
| Feeding Methods | 1 | 2023 | 11 | 0.050 |
Why?
|
| Altitude | 1 | 2003 | 15 | 0.050 |
Why?
|
| Euphorbia | 1 | 2003 | 1 | 0.050 |
Why?
|
| Latex | 1 | 2003 | 5 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2023 | 72 | 0.050 |
Why?
|
| Parturition | 1 | 2023 | 53 | 0.050 |
Why?
|
| Informed Consent | 1 | 2023 | 141 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2025 | 399 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2022 | 59 | 0.050 |
Why?
|
| Serologic Tests | 1 | 2022 | 34 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2022 | 61 | 0.040 |
Why?
|
| Logistic Models | 2 | 2019 | 1269 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2025 | 3153 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2005 | 531 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2003 | 230 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 524 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2023 | 279 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2003 | 226 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2001 | 896 | 0.040 |
Why?
|
| Electrosurgery | 1 | 2020 | 5 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2001 | 59 | 0.040 |
Why?
|
| Cryotherapy | 1 | 2020 | 16 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 387 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 281 | 0.040 |
Why?
|
| Research Personnel | 1 | 2021 | 82 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 643 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2025 | 1698 | 0.040 |
Why?
|
| Hemeproteins | 1 | 1999 | 17 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2019 | 49 | 0.040 |
Why?
|
| Obstetric Labor, Premature | 1 | 1999 | 31 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 325 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 292 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2019 | 76 | 0.040 |
Why?
|
| Vagina | 1 | 2019 | 87 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 542 | 0.040 |
Why?
|
| United States | 2 | 2017 | 8093 | 0.030 |
Why?
|
| Bacteria | 1 | 2021 | 336 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 3485 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 1999 | 197 | 0.030 |
Why?
|
| Iron | 1 | 1999 | 155 | 0.030 |
Why?
|
| Gorilla gorilla | 1 | 2017 | 3 | 0.030 |
Why?
|
| Adenovirus Infections, Human | 1 | 2017 | 3 | 0.030 |
Why?
|
| Ghana | 1 | 2017 | 14 | 0.030 |
Why?
|
| Plasmodium yoelii | 1 | 2017 | 6 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2015 | 919 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2017 | 24 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 205 | 0.030 |
Why?
|
| Plasmids | 1 | 2017 | 294 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 116 | 0.030 |
Why?
|
| Transgenes | 1 | 2017 | 204 | 0.030 |
Why?
|
| Spleen | 1 | 2017 | 474 | 0.030 |
Why?
|
| Histocompatibility Testing | 2 | 2007 | 32 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 180 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 160 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 868 | 0.030 |
Why?
|
| Gene Expression | 1 | 1999 | 852 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 149 | 0.030 |
Why?
|
| Merozoites | 1 | 2015 | 1 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2016 | 107 | 0.030 |
Why?
|
| Macrophages | 1 | 2001 | 1038 | 0.030 |
Why?
|
| Mitochondria | 1 | 1999 | 410 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2014 | 31 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2008 | 1589 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 643 | 0.030 |
Why?
|
| Population Dynamics | 1 | 2013 | 21 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 128 | 0.020 |
Why?
|
| Africa | 1 | 2012 | 30 | 0.020 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 14 | 0.020 |
Why?
|
| Host-Parasite Interactions | 1 | 2012 | 61 | 0.020 |
Why?
|
| Geography | 1 | 2012 | 36 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 105 | 0.020 |
Why?
|
| Arthropod Vectors | 1 | 2011 | 3 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2011 | 37 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 413 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2010 | 28 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2011 | 110 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 5614 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2012 | 483 | 0.020 |
Why?
|
| Papua New Guinea | 1 | 2009 | 8 | 0.020 |
Why?
|
| North America | 1 | 2009 | 114 | 0.020 |
Why?
|
| Neprilysin | 1 | 2008 | 9 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2008 | 37 | 0.020 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2008 | 26 | 0.020 |
Why?
|
| Growth Inhibitors | 1 | 2008 | 24 | 0.020 |
Why?
|
| Antigens, CD19 | 1 | 2008 | 25 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2008 | 193 | 0.020 |
Why?
|
| Topography, Medical | 1 | 2007 | 3 | 0.020 |
Why?
|
| Smallpox | 1 | 2007 | 6 | 0.020 |
Why?
|
| Vaccinia virus | 1 | 2007 | 69 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 497 | 0.020 |
Why?
|
| Bryostatins | 1 | 2005 | 1 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 67 | 0.010 |
Why?
|
| Jaw Neoplasms | 1 | 2004 | 2 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 1979 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 2004 | 22 | 0.010 |
Why?
|
| DNA Probes, HLA | 1 | 2004 | 1 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2004 | 47 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 463 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2004 | 252 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1559 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 426 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 1050 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2001 | 8 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2001 | 30 | 0.010 |
Why?
|
| Fetus | 1 | 2001 | 102 | 0.010 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2001 | 144 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 2001 | 149 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 197 | 0.010 |
Why?
|
| Aging | 1 | 2004 | 771 | 0.010 |
Why?
|